AVA is not currently licensed for PEP, and thus it would have to be given under investigational new drug (IND) protocol or an emergency use authorization (EUA).

AVA is not currently licensed for PEP, and thus it would have to be given under investigational new drug (IND) protocol or an emergency use authorization (EUA).

• A. False
• B. Not applicable
• C. True
• D. Unknown

Answer: (C)

When a drug isn’t approved for a specific use, it can’t be given for that use in routine practice without a regulated pathway that provides access to the investigational product or special authorization. If AVA isn’t licensed for post-exposure prophylaxis, the only ways to use it outside a standard approval are through an investigational new drug process or an emergency use authorization. An IND protocol allows a physician to treat a patient with an investigational drug outside a formal trial, with oversight from the FDA and an institutional review board, often through expanded access. An EUA, issued during a declared public health emergency, can authorize the use of a product not yet approved for a particular indication when no adequate alternatives exist, again under careful safety and efficacy considerations. So, the statement is correct: AVA would have to be given under an IND or an EUA. In contrast, if AVA were licensed for another indication, off-label use could be considered, but that does not apply when the drug isn’t licensed for this PEP use at all.

When a drug isn’t approved for a specific use, it can’t be given for that use in routine practice without a regulated pathway that provides access to the investigational product or special authorization. If AVA isn’t licensed for post-exposure prophylaxis, the only ways to use it outside a standard approval are through an investigational new drug process or an emergency use authorization. An IND protocol allows a physician to treat a patient with an investigational drug outside a formal trial, with oversight from the FDA and an institutional review board, often through expanded access. An EUA, issued during a declared public health emergency, can authorize the use of a product not yet approved for a particular indication when no adequate alternatives exist, again under careful safety and efficacy considerations. So, the statement is correct: AVA would have to be given under an IND or an EUA. In contrast, if AVA were licensed for another indication, off-label use could be considered, but that does not apply when the drug isn’t licensed for this PEP use at all.